One of the biotech stocks highlighted in today’s article is a well-established, large-cap name. The other is a far less established, small-cap player with no products currently on the market. What the two have in common, according to the author, is that both “have made significant breakthroughs — and could provide market-beating returns for many years to come as a result.” For these two biotech stocks to consider – one that currently dominates the cystic fibrosis market and one that is likely to disrupt the diabetes market – CLICK HERE.
The Dominator & The Disruptor: 2 Biotech Stocks To Consider For Market-Beating Returns
Tags:Biotech InvestingBiotech StocksBreakthroughCystic Fibrosis MarketDiabetes MarketInvestment ReturnsinvestorLarge Cap InvestmentsMarket ReturnsStock Marketstocks